The Readout Loud 365: Vinay Prasad’s return, animal testing alternatives, and mRNA upended
6 snips
Aug 14, 2025 Marissa Russo, a STAT fellow and PhD candidate at the Mayo Clinic focusing on glioblastoma, joins to delve into the hotly debated topic of alternatives to animal testing. She explores the innovative methodologies like organ-on-chip models and the push from the FDA and NIH towards more humane research practices. The conversation also touches on the complexities of these new approaches and the challenges in ensuring their reliability. Additionally, insights on the shifting landscape of mRNA technology add to the discussion's depth.
AI Snips
Chapters
Transcript
Episode notes
Vinay Prasad's Controversial Return
- Vinay Prasad was suddenly pushed out of the FDA and has now returned as CBER director amid unanswered questions.
- His reappointment raises concerns about political influence over FDA decisions and internal concessions needed for his return.
mRNA Vaccines Face Political Headwinds
- HHS cuts to BARDA grants and political shifts have chilled investment in mRNA vaccines specifically.
- mRNA therapeutics remain attractive and startups are pivoting toward therapeutic uses like cancer vaccines.
Pivot From Vaccines To Therapeutics
- Companies developing mRNA vaccines should consider pivoting toward therapeutics to retain investor interest and regulatory momentum.
- Expect some vaccine-focused startups to fold while others reallocate resources to therapeutic programs.